Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person IFNAR2:JAK1:STAT2 binds type 1 interferon analogs

Class:Id	Reaction:9696179
_displayName	IFNAR2:JAK1:STAT2 binds type 1 interferon analogs
_doRelease	TRUE
_timestamp	2022-05-10 17:56:33
authored	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20
compartment	[Compartment:984] extracellular region [Compartment:876] plasma membrane
created	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20
edited	[InstanceEdit:9696165] Jassal, Bijay, 2020-07-20 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10
input	[Complex:918193] IFNAR2:JAK1:STAT2 [plasma membrane] [Homo sapiens] [DefinedSet:9696187] type 1 interferon analogs [extracellular region] [Homo sapiens]
isChimeric	FALSE
literatureReference	[LiteratureReference:9696216] Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis [LiteratureReference:9696191] Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study [LiteratureReference:9696199] Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome [LiteratureReference:9734418] Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial [LiteratureReference:9734400] Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial [LiteratureReference:9696152] Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial [LiteratureReference:9734375] Interferon-α2b Treatment for COVID-19 [LiteratureReference:9734378] Corrigendum: Interferon-α2b Treatment for COVID-19 [LiteratureReference:9734392] Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities [LiteratureReference:9734374] The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 [LiteratureReference:9734399] SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial
modified	[InstanceEdit:9717122] Stephan, Ralf, 2021-03-04 [InstanceEdit:9734386] Stephan, Ralf, 2021-06-17 [InstanceEdit:9773229] Matthews, Lisa, 2022-05-03 [InstanceEdit:9773839] Matthews, Lisa, 2022-05-10 [InstanceEdit:9773858] Matthews, Lisa, 2022-05-10 [InstanceEdit:9830342] Matthews, Lisa, 2023-03-08
name	IFNAR2:JAK1:STAT2 binds type 1 interferon analogs
output	[Complex:9696161] IFNAR2:JAK1:STAT2:type 1 interferon analogs [plasma membrane] [Homo sapiens]
releaseDate	2022-06-09
reviewed	[InstanceEdit:9767610] Huddart, Rachel, 2022-03-01
reviewStatus	[ReviewStatus:9821382] five stars
revised	[InstanceEdit:9734417] Stephan, Ralf, 2021-06-16
species	[Species:48887] Homo sapiens
stableIdentifier	[StableIdentifier:9696219] R-HSA-9696179.2
summation	[Summation:9696206] Natural ligands of the IFNAR1/2 receptor include interferon ...
(hasEvent)	[Pathway:909733] Interferon alpha/beta signaling [Homo sapiens] [Pathway:9679191] Potential therapeutics for SARS [Homo sapiens]
[Change default viewing format]

No pathways have been reviewed or authored by IFNAR2:JAK1:STAT2 binds type 1 interferon analogs (9696179)